Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Forma Therapeutics Holdings Inc is a biotechnology business based in the US. Forma Therapeutics shares (FMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Forma Therapeutics employs 139 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$18.09|
|52-week range||$18.57 - $52.75|
|50-day moving average||$23.29|
|200-day moving average||$25.20|
|Wall St. target price||$56.29|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.05|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-3.42%|
|1 month (2021-09-17)||-23.70%|
|3 months (2021-07-16)||-23.18%|
|6 months (2021-04-16)||-29.47%|
|1 year (2020-10-16)||-63.79%|
|2 years (2019-10-13)||N/A|
|3 years (2018-10-13)||N/A|
|5 years (2016-10-13)||N/A|
|Revenue TTM||$7.4 million|
|Gross profit TTM||$-93,367,000|
|Return on assets TTM||-16.81%|
|Return on equity TTM||-26.67%|
|Market capitalisation||$934.5 million|
TTM: trailing 12 months
There are currently 2.8 million Forma Therapeutics shares held short by investors – that's known as Forma Therapeutics's "short interest". This figure is 8.5% down from 3.1 million last month.
There are a few different ways that this level of interest in shorting Forma Therapeutics shares can be evaluated.
Forma Therapeutics's "short interest ratio" (SIR) is the quantity of Forma Therapeutics shares currently shorted divided by the average quantity of Forma Therapeutics shares traded daily (recently around 247207.10526316). Forma Therapeutics's SIR currently stands at 11.4. In other words for every 100,000 Forma Therapeutics shares traded daily on the market, roughly 11400 shares are currently held short.
However Forma Therapeutics's short interest can also be evaluated against the total number of Forma Therapeutics shares, or, against the total number of tradable Forma Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Forma Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Forma Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.121% of the tradable shares (for every 100,000 tradable Forma Therapeutics shares, roughly 121 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Forma Therapeutics.
Find out more about how you can short Forma Therapeutics stock.
We're not expecting Forma Therapeutics to pay a dividend over the next 12 months.
Forma Therapeutics Holdings, Inc. , a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.